ZIOPHARM Oncology Inc (ZIOP)

Symbol Overview

ZIOPhttp://www.nasdaq.com/symbol/ziopHealth Caren/aMedical Specialities

Latest ZIOPHARM Oncology Inc (ZIOP) company news

ZIOPHARM Oncology Announces Updated Findings from Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma Presented at American Academy of Neurological Surgery Annual Meeting

ZIOPHARM Oncology, Inc. (ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that updated data from a subset of patients in its Phase 1 multicenter study of Ad-RTS-hIL-12 + veledimex in patients with recurrent or progressive glioblastoma (GBM) was presented at the 79th Annual Meeting of the American Academy of Neurological Surgery (AANS) in Santa Barbara, CA. Ad-RTS-hIL-12 + veledimex is ZIOPHARM’s adenoviral (Ad) gene therapy candidate for the controlled expression of human interleukin-12 (hIL-12), a critical protein for stimulating an anti-cancer immune response.
" data-reactid="11">BOSTON, Sept. 18, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that updated data from a subset of patients in its Phase 1 multicenter study of Ad-RTS-hIL-12 + veledimex in patients with recurrent or progressive glioblastoma (GBM) was presented at the 79th Annual Meeting of the American Academy of Neurological Surgery (AANS) in Santa Barbara, CA. Ad-RTS-hIL-12 + veledimex is ZIOPHARM’s adenoviral (Ad) gene therapy candidate for the controlled expression of human interleukin-12 (hIL-12), a critical protein for stimulating an anti-cancer immune response.

“We are seeing additional evidence suggestive of inflammatory pseudo-progression rather than tumor progression in patients with recurrent glioblastoma who were biopsied after administration of Ad-RTS-hIL-12 + veledimex,” said E. Antonio Chiocca, M.D., Ph.D., Harvey W. Cushing Professor of Neurosurgery, Department of Surgery, Harvard Medical School, Surgical Director, Center for Neuro-oncology, Dana-Farber Cancer Institute, Chairman, Neurosurgery, Brigham and Women's Hospital and Co-Director, Institute for the Neurosciences, Brigham and Women's Hospital. “These updated immunohistochemistry data on top of promising survival underscore the possible immunomodulatory benefits of localized and controlled IL-12 and support the advancement of this therapy candidate into a larger outcome study.”

Dr. Chiocca’s oral presentation, “A Phase I Clinical Trial of Regulated Interleukin-12 Immunogene Therapy for Recurrent Glioblastoma,” included detail on three biopsied patients with evidence of documented pseudo-progression rather than tumor progression. Pseudo-progression may be seen in post-treatment imaging studies of cancers where the tumor appears larger compared to baseline, but these changes are due to infiltration of immune cells, as evidenced by subsequent biopsies. Some GBM lesions on repeated MRI scans show evidence of progression followed by regression which is consistent with immune-mediated anti-tumor effects.

Dr. Chiocca also provided an overview of trial data previously presented at the 2017 American Society of Clinical Oncology Annual Meeting from patients receiving intratumoral Ad-RTS-hIL-12 with 20 mg of orally-administered veledimex (n = 15) following craniotomy including:

  • A median overall survival (mOS) of 12.5 months for patients with recurrent glioblastoma (GBM) comparing favorably to historical controls;
  • The observed ratio of CD8+/FOXP3+ (effector/suppressor) T cells suggesting overall survival appears correlated with IL-12-mediated cellular immune activation; and
  • A superior survival rate in the 20mg cohort has been observed in those patients that received low dose steroids.

Presentations and Publications section of the Company’s website, http://www.ziopharm.com." data-reactid="19">A copy of the slides from AANS will be available following presentation in the Presentations and Publications section of the Company’s website, http://www.ziopharm.com.

About ZIOPHARM Oncology, Inc.

XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® (RTS®) technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies." data-reactid="21">ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing innovative gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® (RTS®) technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.

Forward-Looking Safe-Harbor Statement


" data-reactid="23">This press release contains certain forward-looking information about ZIOPHARM Oncology, Inc. that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the Company's plans and expectations regarding its securities offerings, fundraising activities and financial strategy, the progress, timing and results of preclinical and clinical trials involving the Company's drug candidates, and the progress of the Company's research and development programs. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied by, the forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to finance our operations and business initiatives and obtain funding for such activities, whether chimeric antigen receptor T cell (CAR-T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, or any of our other therapeutic candidates will advance further in the preclinical or clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether chimeric antigen receptor T cell (CAR-T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, and our other therapeutic products will be successfully marketed if approved; the strength and enforceability of our intellectual property rights; competition from other pharmaceutical and biotechnology companies; and the other risk factors contained in our periodic and interim reports filed from time to time with the Securities and Exchange Commission, including but not limited to, our Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Trademarks
RheoSwitch Therapeutic System® and RTS® are registered trademarks of Intrexon Corporation.

Contact:

David Pitts
Argot Partners
212-600-1902
david@argotpartners.com


ZIOPHARM to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Rodman & Renshaw 19th Annual Global Investment Conference in New York on Tuesday, September 12, 2017 at 12:30 p.m. ET.
" data-reactid="11">BOSTON, Sept. 05, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Rodman & Renshaw 19th Annual Global Investment Conference in New York on Tuesday, September 12, 2017 at 12:30 p.m. ET.

www.ziopharm.com. The webcast will be archived for 90 days." data-reactid="12">To access a live audio webcast of the presentation, please visit the Investor Relations section at www.ziopharm.com. The webcast will be archived for 90 days.

About ZIOPHARM Oncology, Inc.:

XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® (RTS®) technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies." data-reactid="14">ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing innovative gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® (RTS®) technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.


ZIOPHARM Oncology to Participate at Upcoming CAR-TCR Summit

ZIOPHARM Oncology, Inc. (ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that the Company will participate at the upcoming CAR-TCR Summit 2017. The summit is being held September 5-8, 2017 at the Seaport Hotel & World Trade Center in Boston.
" data-reactid="11">BOSTON, Sept. 01, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that the Company will participate at the upcoming CAR-TCR Summit 2017. The summit is being held September 5-8, 2017 at the Seaport Hotel & World Trade Center in Boston.

Laurence Cooper, M.D., Ph.D., Chief Executive Officer of ZIOPHARM, will participate in the Industry Leaders' Fireside Chat on Wednesday, September 6, 2017 beginning at 8:45 a.m. ET. In addition, research highlighting the Sleeping Beauty non-viral gene transfer system will be presented during an oral presentation session.

Sleeping Beauty is one of the most clinically-advanced non-viral cell engineering platforms in development and holds the potential to enable personalized solutions and opens the door to point-of-care manufacturing approaches to rapidly generate T cells, help lower cost, and expand access to innovative therapies,” said Dr. Cooper. “Our human data reveal the therapeutic potential of these genetically modified T cells and the shortened production circumvents the complexities and high cost typically associated with viral-based approaches. Sleeping Beauty offers a scalable solution to redirecting T-cell specificity to both blood cancers and solid tumors using CARs and TCRs."" data-reactid="13">"Sleeping Beauty is one of the most clinically-advanced non-viral cell engineering platforms in development and holds the potential to enable personalized solutions and opens the door to point-of-care manufacturing approaches to rapidly generate T cells, help lower cost, and expand access to innovative therapies,” said Dr. Cooper. “Our human data reveal the therapeutic potential of these genetically modified T cells and the shortened production circumvents the complexities and high cost typically associated with viral-based approaches. Sleeping Beauty offers a scalable solution to redirecting T-cell specificity to both blood cancers and solid tumors using CARs and TCRs."

Details for the oral presentation are as follow:

Title: Sleeping Beauty: An Update on the Non-Viral Transduction Platform for CAR Therapies
Presenter: Partow Kebriaei, Professor, Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center
Track: CAR-TCR Discovery Stream
Date and Time: Thursday, September 7, 2017, 3:20 p.m. – 3:50 p.m. ET

About ZIOPHARM Oncology, Inc.

XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® (RTS®) technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies." data-reactid="17">ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing innovative gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® (RTS®) technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.

Forward-Looking Safe-Harbor Statement


" data-reactid="19">This press release contains certain forward-looking information about ZIOPHARM Oncology, Inc. that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the Company's plans and expectations regarding its securities offerings, fundraising activities and financial strategy, the progress, timing and results of preclinical and clinical trials involving the Company's drug candidates, and the progress of the Company's research and development programs. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied by, the forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to finance our operations and business initiatives and obtain funding for such activities, whether chimeric antigen receptor T cell (CAR-T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, or any of our other therapeutic candidates will advance further in the preclinical or clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether chimeric antigen receptor T cell (CAR-T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, and our other therapeutic products will be successfully marketed if approved; the strength and enforceability of our intellectual property rights; competition from other pharmaceutical and biotechnology companies; and the other risk factors contained in our periodic and interim reports filed from time to time with the Securities and Exchange Commission, including but not limited to, our Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Trademarks
RheoSwitch Therapeutic System® and RTS® are registered trademarks of Intrexon Corporation.

ZIOPHARM Oncology, Inc. breached its 50 day moving average in a Bullish Manner : ZIOP-US : August 29, 2017

*Disclaimer : This is as of previous day’s closing price.

Technical Indicators

Below is a quick look at 5 technical indicators for ZIOPHARM Oncology, Inc.. More studies are available on the Technical Chart.

Indicator Signal
Closing Price above/below 50 Day Moving Average Bullish
Closing Price above/below 200 Day Moving Average Bearish
50 Day Moving Average above/below 200 Day Moving Average Bearish
RSI Reading Level (70) Fair Value
MACD Compared to 9D EMA Signal Line Bullish

View these and more technical studies for ZIOPHARM Oncology, Inc.

Share Price Performance Relative to Peers

From a peer analysis perspective, relative outperformance last month is up from a median performance last year.

While ZIOP-US‘s change in share price of 16.54% for the last 12 months is in line with its peer median, its more recent 30-day share price performance of 6.61% is above the peer median. This suggests the company’s performance has improved more recently relative to peers.

Share Price Performance

Quadrant label definitions. Hover to know more

Leading, Fading, Lagging, Rising

Screen for companies using relative share price performance

Earnings Momentum

ZIOPHARM Oncology, Inc. has an earnings score of 63.69 and has a relative valuation of NEUTRAL.

Stocks with High Earnings Momentum are a preferred option for momentum plays. If they are undervalued, it can be a further advantage and may indicate sustained momentum.

Earnings Momentum Vs Relative Valuation

Quadrant label definitions. Hover to know more

Overvalued, High Earnings Momentum, Undervalued, High Earnings Momentum, UnderValued, Low Earnings Momentum, Overvalued, Low Earnings Momentum

Screen for companies using Earnings Momentum Score

Get Ready for More Acquisitions by Gilead Sciences

Investors woke up Monday morning to a pleasant surprise from Gilead Sciences (NASDAQ:GILD). The big biotech announced plans to acquire Kite Pharma (NASDAQ:KITE) for $11.9 billion. The market applauded the deal, with Gilead stock rising more than 2% in intra-day trading. 

There are several reasons to like the acquisition. Adding Kite's pipeline, particularly lead candidate axicabtagene ciloleucel (axi-cel), makes Gilead an instant leader in cell therapy for treating cancer. But buying Kite Pharma should only be the beginning of acquisitions activity for Gilead. Here are three key reasons why.

Hand holding market up to drawing of big fish about to eat smaller fish with question marks above several of the smaller fish

Image source: Getty Images.

1. Kite isn't enough by itself

The primary reason that Gilead Sciences needed an acquisition was to compensate for continued sales declines for its hepatitis C franchise. As great as buying Kite Pharma should be over the long run, buying Kite isn't enough to turn things around for Gilead by itself.

Gilead stated that the Kite acquisition is "expected to be neutral to earnings by year three and accretive thereafter." These projections assume that axi-cel wins approval in both the U.S. and Europe for treating refractory aggressive non-Hodgkin lymphoma (NHL). I don't question Gilead's estimates -- they're probably solid. However, the company clearly needs a bigger boost to its lineup to offset its hep C woes.

CEO John Milligan has stated that Gilead wanted a "transformative" deal. Buying Kite meets that qualification in terms of positioning the biotech in oncology. However, it's not transformative from a financial standpoint. 

2. Gilead has hinted at more deals

In the conference call discussing the Kite Pharma acquisition, Milligan stated that Gilead would be "quite interested in things that would augment cellular therapy." He added that the company would not be "going quietly after this deal," with the business development group staying "very active" evaluating opportunities. You don't have to read between the lines to suspect that more deals could be on the way.

With cell therapy now the cornerstone of Gilead's oncology strategy, one obvious potential takeover candidate is Ziopharm Oncology (NASDAQ:ZIOP). Ziopharm has a solid pipeline of chimeric antigen receptor T cell (CAR T) and T cell receptor (TCR) therapies. However, Ziopharm isn't as far along with its development program as Kite is.  

When Milligan has talked about potential acquisitions in the past, he has primarily discussed oncology but also mentioned inflammation and non-alcoholic steatohepatitis (NASH). It wouldn't be surprising if Gilead move forward with deals in either or both of these therapeutic categories. 

Earlier this year, Gilead CFO Robin Washington stated that the company's top priority is to "focus on growth for the top line." The problem is that most of the possible acquisition targets in oncology, inflammation, and NASH wouldn't move the needle much in the near term for boosting revenue by themselves, meaning that Gilead would need multiple deals to make a significant impact.  

3. There's plenty of cash to spend

Then there's Gilead's still-huge cash stockpile. The company reported cash, cash equivalents, and marketable securities totaling $36.6 billion at the end of the second quarter. Gilead plans to use a combination of cash, bank debt, and senior unsecured notes to fund the Kite Pharma buyout. Even if the biotech pulled only from its cash, Gilead would still have nearly $25 billion after acquiring Kite -- and that's before adding cash made in the second half of 2017. 

John Milligan has stated in the past that "you can't buy shares back into prosperity." Gilead has done plenty of stock repurchases in the past, but don't expect the company to use much of its cash in this way going forward. And while Gilead is likely to keep its string of dividend hikes going, the company isn't likely to pour most of its money into higher dividends. The best use of Gilead's cash is in making more acquisitions that provide additional revenue relatively soon. You know it, I know it, and Gilead knows it.

Gilead could afford to buy Ziopharm Oncology at a similar premium to what it paid for Kite with its cash flow. It could buy several of the leading biotechs in NASH without making a huge dent in its cash position. The company could even afford to gobble up a couple of other mid-cap oncology biotechs without breaking a sweat.

I have thought for a while that a "string of pearls" strategy of acquiring multiple small and mid-sized biotechs could be a smart approach for Gilead Sciences. It seems that's the direction the company is heading down with the pending acquisition of Kite Pharma as the first pearl on the necklace.

Leave a Reply

Your email address will not be published. Required fields are marked *